PF-06459988 - CAS 1428774-45-1
Catalog number: B0084-475427
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C19H22ClN7O3
Molecular Weight:
431.88
COA:
Inquire
Targets:
EGFR
Description:
PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including the secondary acquired resistance mutation T790M.PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. Preclinical trials in Non-small cell lung cancer in USA is on-going.
Publication citing BOC Sciences Products
1. Specificity Screening of Potential Active Components from Moutan Cortex for Rat Mesangial Cells HBZY-1 by Cell Membrane Immobilized Chromatography
2. Inhibition of pro‑collagen I expression by oxymatrine in hepatic stellate cells is mediated via nuclear translocation of Y‑box binding protein 1
3. Development of a convenient method for the determination of dimethyl sulfoxide in lyophilised pharmaceuticals by static headspace gas chromatography–mass spectrometry
4. Design and development of permeation enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for ceftriaxone sodium improved oral pharmacokinetics
5. Inhibition studies of the synergistic effect of chemical compounds on 3CR12 ferritic steel corrosion in acid solutions
6. Machine learning models identify molecules active against the Ebola virus in vitro

>> More

Purity:
98%
Appearance:
white to beige powder
Synonyms:
PF-06459988; PF06459988; PF 06459988; PF-6459988; PF 6459988; PF6459988; 1-((3R,4R)-3-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-methoxypyrrolidin-1-yl)prop-2-en-1-one
Solubility:
DMSO: soluble5 mg/mL, clear
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Non-small cell lung cancer
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChI:
InChI=1S/C19H22ClN7O3/c1-4-15(28)27-7-11(14(9-27)29-3)10-30-18-16-13(20)6-21-17(16)24-19(25-18)23-12-5-22-26(2)8-12/h4-6,8,11,14H,1,7,9-10H2,2-3H3,(H2,21,23,24,25)/t11-,14+/m1/s1
Canonical SMILES:
C=CC(N1C[C@H](COC2=C3C(NC=C3Cl)=NC(NC4=CN(C)N=C4)=N2)[C@@H](OC)C1)=O
Current Developer:
Originator Pfizer
1.Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H;Nair SK;Murray BW;Almaden C;Bailey S;Baxi S;Behenna D;Cho-Schultz S;Dalvie D;Dinh DM;Edwards MP;Feng JL;Ferre RA;Gajiwala KS;Hemkens MD;Jackson-Fisher A;Jalaie M;Johnson TO;Kania RS;Kephart S;Lafontaine J;Lunney B;Liu KK;Liu Z;Matthews J;Nagata A;Niessen S;Ornelas MA;Orr ST;Pairish M;Planken S;Ren S;Richter D;Ryan K;Sach N;Shen H;Smeal T;Solowiej J;Sutton S;Tran K;Tseng E;Vernier W;Walls M;Wang S;Weinrich SL;Xin S;Xu H;Yin MJ;Zientek M;Zhou R;Kath JC J Med Chem. 2016 Mar 10;59(5):2005-24. doi: 10.1021/acs.jmedchem.5b01633. Epub 2016 Jan 28.
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR. A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.
2.Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Planken S;Behenna DC;Nair SK;Johnson TO;Nagata A;Almaden C;Bailey S;Ballard TE;Bernier L;Cheng H;Cho-Schultz S;Dalvie D;Deal JG;Dinh DM;Edwards MP;Ferre RA;Gajiwala KS;Hemkens M;Kania RS;Kath JC;Matthews J;Murray BW;Niessen S;Orr ST;Pairish M;Sach NW;Shen H;Shi M;Solowiej J;Tran K;Tseng E;Vicini P;Wang Y;Weinrich SL;Zhou R;Zientek M;Liu L;Luo Y;Xin S;Zhang C;Lafontaine J J Med Chem. 2017 Apr 13;60(7):3002-3019. doi: 10.1021/acs.jmedchem.6b01894. Epub 2017 Mar 29.
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective. Secondary oncogenic EGFR mutations account for approximately 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective. The discovery of PF-06459988 (1), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.1 Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clinical candidate PF-06747775 (21), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties. Compound 21 is currently being evaluated in phase-I clinical trials of mutant EGFR driven NSCLC.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products

CAS 1035638-91-5 PF 6274484

PF 6274484
(CAS: 1035638-91-5)

PF 6274484 is a high affinity and potent covalent EGFR kinase inhibitor (Ki = 0.14 nM). It inhibits the autophosphorylation of wild-type EGFR in A549 cells and ...

ZD-4190
(CAS: 413599-62-9)

ZD-4190, a substituted 4-anilinoquinazoline, is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of e...

CAS 63177-57-1 Methyl 2,5-dihydroxycinnamate

Methyl 2,5-dihydroxycinnamate
(CAS: 63177-57-1)

Methyl 2,5-dihydroxycinnamate, a stable analog of erbstatin, is a stable, potent inhibitor of EGFR kinase activity. It is described to be four-times more stable...

CAS 850140-72-6 Afatinib

Afatinib
(CAS: 850140-72-6)

Afatinib irreversibly inhibits EGFR/HER2 including EGFR, EGFR(L858R), EGFR(L858R/T790M) and HER2. It is 100-fold more active against Gefitinib-resistant L858R-T...

CAS 133550-41-1 AG 556

AG 556
(CAS: 133550-41-1)

AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...

CAS 133550-37-5 Tyrphostin B44, (+) enantiomer

Tyrphostin B44, (+) enantiomer
(CAS: 133550-37-5)

Tyrphostin B44, (+) enantiomer is an inhibitor of epidermal growth factor receptor (EGFR) kinase (IC50 = 0.86 μM). Less active than the (-) enantiomer.

CAS 1353550-13-6 Olmutinib

Olmutinib
(CAS: 1353550-13-6)

Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inh...

CAS 170449-18-0 AG 1478 hydrochloride

AG 1478 hydrochloride
(CAS: 170449-18-0)

The hydrochloride salt form of AG 1478, which has been found to be an epidermal growth factor receptor tyrosine kinase inhibitor.

Quick Inquiry

Verification code

Featured Items